MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s12029-026-01474-2

Медицинская библиотека · Journal of gastrointestinal cancer · 2026

Exclusive Neoadjuvant Chemotherapy with the FLOT Regimen Protocol in Resectable Gastric Cancer: A Retrospective Cohort Study in a Brazilian Reference Center.

Araújo Kelre Wannlen Campos Silva, Ronchi Fernanda Carneiro, Stecca Carlos Eduardo, Júnior Carlos Roberto Naufel, Nocete Paulo Henrique, de Sena Rayssa Helena, Ferreira Renata Medeiros, Nonato Emily Karoline Araujo

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) is the standard treatment for resectable gastric cancer. However, adherence to postoperative cycles is frequently poor, and in the Brazilian public health system, FLOT is reimbursed only in the neoadjuvant setting. This has led to the adoption of an alternative approach delivering all eight cycles preoperatively. We evaluated the feasibility, safety, and outcomes of this exclusive neoadjuvant strategy.

METHODS

We retrospectively analyzed 32 patients with resectable gastric cancer treated between 2019 and 2024. Patients were grouped according to the number of neoadjuvant cycles received (≤ 4 vs. > 4). Clinical outcomes included treatment adherence, R0 resection rate, overall survival (OS), disease-free survival (DFS), pathological complete response (ypT0N0) rate, and toxicity. Kaplan-Meier curves, log-rank test, and hazard ratio were used in the analysis.

RESULTS

Twenty-one patients (65.6%) completed all eight preoperative cycles. Five patients (15.7%) received ≤ 4 cycles, while 27 (84.3%) received > 4 cycles. The R0 rate was 75%. Median OS was 45.3 months for patients receiving > 4 cycles versus 18.6 months for those with ≤ 4 cycles (p = 0.0096). Median DFS was 41.1 months vs. 18.6 months, respectively (p = 0.028). Pathological complete response was achieved in 9.4% of patients. Toxicity was manageable, although 50% required dose adjustments.

CONCLUSION

Delivering all eight cycles of FLOT exclusively in the neoadjuvant setting was feasible and safe in this Brazilian cohort, with high adherence and favorable survival outcomes. This approach may represent a viable alternative in contexts with low adherence to adjuvant treatment or limited access to postoperative chemotherapy.

Для цитирования: Araújo Kelre Wannlen Campos Silva, Ronchi Fernanda Carneiro, Stecca Carlos Eduardo, Júnior Carlos Roberto Naufel, Nocete Paulo Henrique, de Sena Rayssa Helena, Ferreira Renata Medeiros, Nonato Emily Karoline Araujo. Exclusive Neoadjuvant Chemotherapy with the FLOT Regimen Protocol in Resectable Gastric Cancer: A Retrospective Cohort Study in a Brazilian Reference Center.. Journal of gastrointestinal cancer. 2026. DOI: 10.1007/s12029-026-01474-2.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.